echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Front Immunol: Clinical experience on the efficacy and safety of proteasome inhibitor bortezomib in the treatment of severe systemic lupus erythematosus

    Front Immunol: Clinical experience on the efficacy and safety of proteasome inhibitor bortezomib in the treatment of severe systemic lupus erythematosus

    • Last Update: 2021-11-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com





    In summary, in most patients with severe SLE manifestations that do not respond to conventional immunosuppressive agents, a good therapeutic effect of the combination of BTZ and corticosteroids has been observed


    Literature source: Walhelm T, Gunnarsson I, Heijke R, Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study.


     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.